Vor Biopharma (NYSE:VOR) Earns Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note released on Tuesday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

VOR has been the subject of several other research reports. Robert W. Baird reduced their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a report on Tuesday. Barclays dropped their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a research note on Monday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $11.36.

Vor Biopharma Trading Down 2.9 %

Shares of VOR stock opened at $1.01 on Tuesday. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14. The stock has a market capitalization of $69.36 million, a P/E ratio of -0.61 and a beta of -0.37. The firm’s 50 day moving average is $0.78 and its 200 day moving average is $0.93.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). As a group, equities analysts predict that Vor Biopharma will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after acquiring an additional 69,436 shares during the period. Acadian Asset Management LLC grew its position in shares of Vor Biopharma by 51.4% during the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares in the last quarter. Renaissance Technologies LLC raised its stake in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares during the period. Hsbc Holdings PLC raised its stake in Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the 2nd quarter worth approximately $53,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.